Key result
Cancer risk-reducing interventions may raise ASCVD risk, warranting systematic cardiovascular risk assessment.
Cancer risk-reducing interventions can inadvertently increase cardiovascular risk, necessitating proactive cardiovascular risk assessment and management in this unique population.
May warrant CV risk assessment during cancer prevention counseling; leaves open optimal integrated strategies pending prospective trials.
Despite impressive advances in diagnosis and treatment, cancer remains a serious disease with a significant risk of recurrence and death. Although personalized and less toxic therapies have decreased the public health burden associated with many cancer types, the ideal cancer-mitigating intervention
No takes yet. Share an insight, caveat, or question.
Oren et al. (2020) conducted a review in High risk of developing cancer. Cancer risk-reducing therapies (e.g., prophylactic oophorectomy, NSAIDs) was evaluated. Cancer risk-reducing interventions, such as prophylactic oophorectomy or long-term NSAID use, may increase the risk of atherosclerotic cardiovascular disease, necessitating systematic cardiovascular risk assessment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: